Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals develops biotechnology medicines for serious diseases and conditions, with commercial franchises in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. Company news commonly covers CFTR modulators including ALYFTREK and TRIKAFTA, the CRISPR/Cas9 gene-edited therapy CASGEVY, and JOURNAVX, an oral non-opioid pain signal inhibitor.
Updates also track financial results, regulatory approvals and label expansions, reimbursement and patient-access agreements, clinical data presentations, and pipeline programs in kidney disease, neuropathic pain, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1. Vertex disclosures frequently connect revenue trends with progress across approved products and investigational programs such as povetacicept for IgA nephropathy.
Vertex (Nasdaq: VRTX) completed its acquisition of Crinetics Pharmaceuticals (Nasdaq: CRNX) on September 1, 2026, under a previously announced definitive agreement valuing Crinetics at approximately $10.0 billion, or about $8.8 billion net of estimated cash acquired. According to Vertex, the deal adds PALSONIFY (paltusotine), the first once-daily oral therapy for acromegaly, and atumelnant, an oral ACTH receptor antagonist in Phase 3 for congenital adrenal hyperplasia and Phase 2 for Cushing’s syndrome, plus additional endocrine programs.
Vertex said PALSONIFY and atumelnant together have potential to generate more than $5 billion in peak annual revenue and expects the transaction to become accretive to non-GAAP operating income in 2029. The acquisition establishes rare endocrine diseases as a new growth pillar. Vertex also expanded its leadership team: Charles Wagner will oversee Crinetics integration as EVP, COO; Jonathan Poole will become EVP, CFO effective January 1, 2027; and Jasper van Grunsven will join on September 8, 2026 as EVP, Chief Pain and New Product Planning Officer.
Vertex (Nasdaq: VRTX) announced that its management team will participate in four investor conferences in September 2026, including events hosted by Wells Fargo, Cantor, Morgan Stanley and Bank of America in Boston, New York and London. The sessions will feature fireside chats with senior investor relations leaders and the CEO. Live webcasts and archived replays will be available on Vertex’s website in the Investors > News and Events section.
Crinetics Pharmaceuticals (Nasdaq: CRNX) reported second-quarter 2026 revenue of $25.1 million, up from $1.0 million a year earlier, including $24.0 million in PALSONIFY net product revenue following its U.S. launch. Net loss was $120.9 million, or $1.14 per share. Cash, cash equivalents and investment securities totaled $1.2 billion at June 30, 2026.
On July 6, 2026, Vertex Pharmaceuticals (Nasdaq: VRTX) and Crinetics entered a definitive agreement for Vertex to acquire Crinetics for $85.00 per share in cash, implying total equity value of about $10.0 billion, or $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both boards and is expected to close in the third quarter of 2026, subject to regulatory and Crinetics stockholder approvals. Crinetics also received FDA Rare Pediatric Disease Designation for Phase 3 candidate atumelnant in classic congenital adrenal hyperplasia and withdrew financial guidance due to the pending transaction.
Vertex (Nasdaq: VRTX) reported second quarter 2026 total revenue of $3.33 billion, up 12% year over year, driven by cystic fibrosis therapies, CASGEVY, and JOURNAVX. U.S. revenue was $2.06 billion (+11%), and revenue outside the U.S. was $1.28 billion (+14%).
Combined GAAP and non-GAAP R&D, acquired IPR&D and SG&A expenses were $1.6 billion and $1.4 billion, respectively, versus $1.4 billion and $1.2 billion a year ago. GAAP and non-GAAP net income were $1.1 billion and $1.2 billion. Cash and marketable securities rose to $13.6 billion.
Vertex raised 2026 total revenue guidance to $13.1–$13.2 billion, embedding at least $0.5 billion of non-CF product revenue, and reiterated expense guidance. The company agreed to acquire Crinetics Pharmaceuticals, expects closing in Q3 2026, and advanced its pipeline, including a povetacicept BLA for IgAN with a PDUFA date of November 30, 2026.
AbCellera (Nasdaq: ABCL) announced a collaboration with Vertex Pharmaceuticals (Nasdaq: VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera will use its proprietary TCE platform to lead discovery and early development activities, while Vertex will fund all research and development costs and hold the rights to develop and commercialize resulting multispecific antibodies.
According to AbCellera, it will receive $28 million in total upfront payments and may earn additional preclinical, development, regulatory, and commercial milestone payments, plus tiered royalties on net sales. The companies may also mutually agree for AbCellera to conduct cell line development, process development, and clinical manufacturing through Phase 1 for collaboration programs.
Vertex (Nasdaq:VRTX) will report its Q2 2026 financial results on Monday, August 3, 2026, after market close. A conference call and live webcast are scheduled for 4:30 p.m. ET, accessible via phone or through the Investors section of the company website.
Vertex (Nasdaq: VRTX) will acquire Crinetics (Nasdaq: CRNX) for $85 per share in cash, implying equity value of about $10 billion, or $8.8 billion net of cash. The deal, unanimously approved by both boards, is expected to close in Q3 2026.
The acquisition adds commercial acromegaly drug PALSONIFY and Phase 3 CAH candidate atumelnant. Vertex expects immediate revenue contribution from PALSONIFY, combined peak annual revenue of >$5 billion, and accretion to non-GAAP operating income in 2029. Financing will use cash plus debt, including $4.5 billion in committed bridge funding.
Vertex (Nasdaq: VRTX) received US FDA approval to expand use of CASGEVY (exagamglogene autotemcel) to people ages 2 years and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
CASGEVY is the first approved genetic therapy for these conditions in children as young as 2, making approximately 5,500 additional US children eligible. Vertex reports more than 75 authorized treatment centers are activated in the US, and regulatory review for label expansion is underway in the Kingdom of Saudi Arabia and the United Kingdom.
Vertex (Nasdaq: VRTX) reported new Phase 3 data on CASGEVY in children ages 5–11 with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).
All evaluable SCD patients (8/8) were VOC-free ≥12 months, and all evaluable TDT patients (8/8) achieved ≥12 months transfusion independence, supporting ongoing global regulatory submissions for younger children.
Vertex (Nasdaq: VRTX) presented new Phase 3 and long-term data for ALYFTREK and TRIKAFTA in young children with cystic fibrosis at the European Cystic Fibrosis Conference.
Key results include large reductions in sweat chloride, 96‑week safety data in patients ≥6, and plans for global regulatory submissions starting in 2026.